Lucas De Breed

Lucas is the Founder of August Care (AUGC), offering Outcomes-based Financial Solutions® for the commercialization of precision medicines. August’s mission is to enable early and broad access to patients and ensuring sustainability for precision medicine in the context of ever-rising healthcare costs. August serves both pharma and payers through its suite of solutions.
Lucas has over a decade of international experience in all phases of drug development and commercialization, combined with a background in finance and investment. Previously as a Manager at Deallus, a global strategy consulting firm serving Top 30 Pharma clients, he was responsible for the oncology business unit and founded the firm’s East Coast office in New York City. Consequently, as a Managing Director at Akero Health, he advised half a dozen early-stage therapeutics, medtech and diagnostics companies in both New York City and the San Francisco Bay Area. As an Investment Director at INKEF Capital, a leading European healthcare and technology venture capital firm, he committed approximately $120 million to US and European biotech start-ups in the therapeutic areas of oncology, audiology, fibrosis, neuromuscular disorders, metabolic diseases and monogeneic diseases, and served on the respective Boards. While at INKEF Capital, he was instrumental in setting the investment strategy, building out the investment team, and driving the AUM expansion to $600 million.
Lucas holds a PhD from University College London and an MBA from Stanford University. He has co-authored several scientific papers. He serves on the the Board of Directors of QuantumLeap Healthcare Collaborative, the Scientific Advisory Board of Promontory Therapeutics, and the Advisory Board of F1RST, an early-stage investment fund focused on regenerative medicine.